Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
OBJECTIVE
To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB).


METHODS
We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder.


RESULTS
Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases the bladder capacity by causing bladder relaxation during the storage phase.


CONCLUSIONS
Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.
Department of Pharmacology, Hamdard Institue of Medical Sciences and Research and Associated Hakeem Abdul Hameed Centenary Hospital, Jamia Hamdard, New Delhi-110062, India. drimran@aol.in.
Mohammed
M
Imran
Abul Kalam
AK
Najmi
Shams
S
Tabrez
D000083:Acetanilides / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy
D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D018727:Muscarinic Antagonists; D013844:Thiazoles; C520025:mirabegron